Skip to main content

Closed

SABS: SAB Biotherapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth-100.0% / yr

Operating margin0.0%

ROIC-24.3%

Financially safe

Stretched

Debt / equity0.03×

Interest coverage-248.8×

Current ratio11.45×

Valuation

Unrated

P/E ratio8.3×

SAB Biotherapeutics, Inc.

SABSNASDAQ·USD·Closed

SAB Biotherapeutics, Inc.

SABSNASDAQ·USD·Closed

$3.57

+0.28%

$3.57

+$0.01 (0.28%)

52W Range

52thpctl

Volume

0.45×avg

Mkt Cap

34.12MUSD

P/E

8.3TTM

Div Yield

–ann

52W Range

52thpctl

Volume

0.45×avg

Market Cap

34.12MUSD

P/E Ratio

8.3TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings